|Bid||3.4100 x 800|
|Ask||3.4300 x 1400|
|Day's Range||3.3400 - 3.4400|
|52 Week Range||2.4300 - 16.3500|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.35|
Diplomat Pharmacy, Inc. (NYSE:DPLO) investors will be delighted, with the company turning in some strong numbers with...
Diplomat Pharmacy Inc (NYSE: DPLO) cautioned investors on Tuesday that it has "substantial doubts" related to its ability to continue functioning as a business. Wells Fargo analyst Jamie Stockton maintained a Market Perform rating on Diplomat with a price target lowered from $5.50 to $3. If the company opts not to sell itself and remain public, it would be valued at eight times EV/EBITDA on EBITDA estimates of $85 million, the analyst said.
Shares of Diplomat Pharmacy Inc. took a record dive Tuesday after the specialty pharmacy company disclosed a “going concern” warning as the company reported a much wider-than-expected loss for a third straight quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD, the senior secured rating to Caa1 from B3 and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3. The downgrade of the Corporate Family Rating to Caa1 from B3 reflects the recent decision by a large payer to begin excluding Diplomat from its specialty pharmacy network later this month, raising concerns about Diplomat's competitive position.
Shares of Diplomat Pharmacy, Inc. (NYSE: DPLO), a Flint, Michigan-based independent provider of specialty pharmacy and infusion services, plummeted more than 50% Tuesday after the company warned investors it faces an existential threat. Revenue declined year-over-year from $1.373 billion to $1.301 million, and the pharmacy benefit manager segment revenue fell from $170 million to $82 million as the segment's total volume fell from 1,931,000 to 922,000. Diplomat's earnings report includes a warning that it may not be able to meet its total net leverage and interest coverage ratio covenants as part of its credit agreement for the period ending Dec. 31, 2019.
Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
3rd Quarter Revenue of $1,301 Million , compared to $1,373 Million , Net Loss of $177 Million , compared to Net Income of $0.2 Million , Adjusted EBITDA of $11.5 Million , compared to $41.9 Million FLINT, ...
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
FLINT, Mich. , Oct. 30, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) will release its third-quarter 2019 operating results before market open Tuesday, Nov. 12 . A conference call and live ...
It's nice to see the Diplomat Pharmacy, Inc. (NYSE:DPLO) share price up 11% in a week. But only the myopic could...
FLINT, Mich., Oct. 16, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), effective today, has completed the sale of certain assets of Envoy Health Management, LLC to Diligent Health Solutions, LLC, a multifaceted healthcare communication center. The contracts administered at the Chantilly, Virginia location as well as associated Envoy Health Management employees have been transferred to Diligent Health Solutions. Diplomat is retaining a portion of the Envoy Health Management operations, specifically the portion operated out of the Flint, Michigan location, which will continue to specialize in digital therapeutics and pharmaceutical services.
Following the retirement of Chris Luthin, David Skomo Appointed COO at CastiaRx. FLINT, Mich., Oct. 2, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), has appointed David Skomo as chief operating officer of CastiaRx following the retirement of Chris Luthin. CastiaRx, a division of Diplomat, is a pharmacy benefit manager (PBM) that helps healthcare payers manage specialty pharmacy costs.
Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B3 from B2, the Probability of Default Rating to B3-PD from B2-PD, and the senior secured rating to B3 from B2. At the same time, Moody's affirmed the SGL-3 Speculative Grade Liquidity Rating.
Diplomat Pharmacy, Inc. (NYSE: DPLO ) reported second-quarter earnings at $2.13 per share. The company reported revenue of $1,288 million, compared to $1,416 million last year. Despite the positive earnings ...
2nd Quarter Revenue of $1,288 Million , compared to $1,416 Million , Net Loss of $159.5 Million , compared to a Net Loss of $4.0 Million , Adjusted EBITDA of $19.3 Million , compared to $42.7 Million FLINT, ...
At the direction of its Board of Directors, the company is reviewing strategic alternatives focused on maximizing shareholder value. The strategic alternatives expected to be considered include, but are not limited to, a sale or merger of the Company, continuing to pursue value-enhancing initiatives as a standalone company, capital structure changes, or the sale or other disposition of certain of the Company's businesses or assets. Diplomat has retained Foros Securities LLC as financial advisor and Sidley Austin LLP as legal advisor to assist with its strategic alternatives review.
This innovative agreement forms the nation's first large-scale physician practice-based infusion program. FLINT, Mich., Aug. 8, 2019 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), is pleased to announce an exclusive agreement between Diplomat and Allergy Partners, P.A., to manage in-office and in-home delivery and administration of infusion drugs and biologics. Allergy Partners is the nation's largest independent, single-specialty practice for allergic disease, asthma, and immunology.
Diplomat Pharmacy (NYSE: DPLO ) unveils its next round of earnings this Friday, August 9. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Sell-side ...